Axsome Therapeutics (AXSM) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Axsome Therapeutics (AXSM)

An SI Board Since March 2017

Posts	SubjectMarks	Bans	Symbol
32	6	0	AXSM

Emcee: BioHero	Type: Moderated

Introduction Market Data Compact

Undiscovered and massive undervalued Biotech Stock with many Big News on the way . Axsome has 5 Phase 3 in various indication targeting very large Markets including Alzheimer and Depression .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .

This undiscovered Stock could be the next 10 bagger if only one of their 5 Phase 3 program is successful .GL

Axsome (AXSM)

Market-Cap: $83 Million
Cash: $50.6 Million (cash runway into the first quarter of 2019)
Price:$3.60

Shares Out: 23 Million

Anticipated Near-Term Clinical Milestones

AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions in Phase 3 (SPA & Fast Track) ---7M patients in the U.S.

AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) ---No approved drug = high unmet need. 80,000 new cases per year in the U.S.

AXS-02 Chronic Low Back Pain Associated with Modic Changes in Phase 3 ---1.6M patients in the U.S.

AXS-05 Agitation in patients with Alzheimer’s disease(AD) in Phase 2/3 ---No approved medication = unmet medical need. 2M patients in the U.S.

AXS-05 STRIDE-1 Treatment resistant depression in Phase 3 ---Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

New Presentation March 31
phx.corporate-ir.net

Major Shareholders

Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
32	Don't have a clue how they'd have patent protection for this molecule.	scaram(o)uche	-	1/8/2019
31	warrants....... surprised, there aren't many out...... 2.1m (one share	scaram(o)uche	-	1/8/2019
30	So the bold statement at the end of yesterday's second PR? ATM was pretty m	scaram(o)uche	-	1/8/2019
29	latest 10-Q.... In October 2017, the Company entered into a sales agreement (th	scaram(o)uche	-	1/8/2019
28	Oh man, you can just feel the coffers filling. Is there any criticism of the da	scaram(o)uche	-	1/8/2019
27	Can't get my arms around what happened today. Stunned. They sold into the	scaram(o)uche	-	1/7/2019
26	AXSM = Market Cap $70 Million / Cash $41 Million or untill Q4 2019 / Shares Out	BioHero	-	1/17/2018
25	AXSM could be the next 4 - 6 bagger biotechstockhttps://www.tradingview.com/char	BioHero	-	12/28/2017
24	Looks like the runup to phase 3 results has just begun...GL "JPMorgan Chas	BioHero	-	12/28/2017
23	Looks like breakout is on the way ..2x Phase 3 readout expected within day	BioHero	-	12/26/2017
22	Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc....Decem	BioHero	-	12/22/2017
21	2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM AXSM (MC $120 M) (Cash $40	BioHero	-	12/20/2017
20	MACD and RSI(14) show bullish signs. [graphic]	hollyhunter	-	7/30/2017
19	Ladenburg Thalmann raised its price target on Axsome Therapeutics (NASDAQ: AXSM)	BioHero	-	7/26/2017
18	Nice price jump looks like its on the way to break the size back the MA(200) at	BioHero	-	6/20/2017
17	Fantastic new director appointed ,, she really must like what she sees at Axsome	BioHero	-	6/19/2017
16	Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days.....	BioHero	-	6/6/2017
15	Almost 1.9 Million shares bought by new institutional investors alone in this mo	BioHero	-	5/25/2017
14	Another nice move today, next near term tgt is to size back the MA(200) at aroun	BioHero	-	5/22/2017
13	and another buy rating out today with tgt $14 thefly.com Axsome Therapeutics	BioHero	-	5/19/2017
12	Another Guy likes AXSM ...more and more people discover this stock and realize t	BioHero	-	5/16/2017
11	Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Th	BioHero	-	5/12/2017
10	Well written article out by J.Napodano Should You Invest In Axsome Therapeutic	BioHero	-	5/9/2017
9	Fantastic News out today... Axsome Therapeutics Receives FDA Fast Track Designa	BioHero	-	5/8/2017
8	New Investor bought a MASSIVE stake of 1.3 Million shares 5.5% , now the majorit	BioHero	-	4/28/2017

Go to reply# or date (mm/dd/yy):